Physician profile
Surabhi Pathak
NPI 1285999284
$1,393.24
in general payments reported to CMS, 2019-2025
22 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.03 · 2020: $11.30 · 2021: $95.12 · 2022: $260 · 2023: $350 · 2024: $453 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $262.18 | 2023-2025 | |
| Pfizer INC. | $186.87 | 2019-2025 | |
| Gilead Sciences, INC. | $159.73 | 2022-2025 | Trodelvy |
| Celgene Corporation | $132.12 | 2021-2024 | Reblozyl, Onureg |
| E.R. Squibb & Sons, L.L.C. | $107.81 | 2020-2025 | Opdivo |
| Janssen Biotech, INC. | $62.59 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Seagen INC. | $55.08 | 2021-2023 | Tukysa |
| Daiichi Sankyo INC. | $54.97 | 2022 | |
| Abbvie INC. | $50.89 | 2022-2025 | |
| Amgen INC. | $49.42 | 2021-2022 | |
| Glaxosmithkline, LLC. | $45.62 | 2024 | Zejula |
| Merck Sharp & Dohme LLC | $37.19 | 2019-2024 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $30.93 | 2023 | Ninlaro |
| Genzyme Corporation | $30.75 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $22.94 | 2024 | Onivyde |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $19.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.70 | 2021 | |
| Karyopharm Therapeutics INC. | $15.48 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $14.00 | 2023 | Epkinly, Imbruvica |
| Puma Biotechnology, INC. | $13.96 | 2023 | |
| Array Biopharma INC | $12.79 | 2022 | |
| Novocure INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surabhi Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.